+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tumor-Infiltrating Lymphocyte Therapy Market by Indication, Cell Source, End User, Distribution Channel, Manufacturing Model - Global Forecast to 2030- Product Image
Tumor-Infiltrating Lymphocyte Therapy Market by Indication, Cell Source, End User, Distribution Channel, Manufacturing Model - Global Forecast to 2030- Product Image
Sale

Tumor-Infiltrating Lymphocyte Therapy Market by Indication, Cell Source, End User, Distribution Channel, Manufacturing Model - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081124
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Introduction to the Tumor-Infiltrating Lymphocyte Therapy Landscape

Tumor-infiltrating lymphocyte therapy harnesses the body’s own immune cells to target malignant tumors directly. Over the past decade, this adoptive cell therapy approach has evolved from experimental protocols into a promising treatment modality for solid tumors. By isolating lymphocytes from patient tumor biopsies, expanding them ex vivo, and reinfusing highly active cytotoxic populations, clinicians can deliver personalized immunotherapy with the potential for durable responses.

In this executive summary, we outline the critical shifts transforming the TIL therapy landscape, examine the cumulative impact of upcoming United States tariffs on supply chains, uncover key segmentation and regional dynamics, highlight leading industry players, and offer actionable recommendations for decision-makers. Our goal is to equip stakeholders with a concise yet comprehensive understanding of current trends and strategic imperatives, paving the way for informed investment and development decisions.

Transformative Shifts in the Tumor-Infiltrating Lymphocyte Therapy Landscape

Over the last five years, TIL therapy has undergone transformative shifts driven by clinical successes, manufacturing breakthroughs, and evolving regulatory frameworks. Innovations in cell expansion protocols have reduced culture times from several weeks to days, enhancing product consistency and lowering costs. Concurrently, advances in neoantigen profiling and single-cell sequencing have refined patient selection, boosting response rates in melanoma and emerging indications such as lung and breast cancer.

Regulatory bodies have responded to promising outcomes by streamlining approval pathways. Breakthrough therapy designations and accelerated review timelines now enable earlier patient access, while harmonization efforts across major markets facilitate global clinical trial enrollment. Technology alliances between biotechs and contract development organizations have scaled manufacturing capacity, leveraging automation and closed-system bioreactors to support commercial-scale production.

Taken together, these developments signal a maturation of the TIL therapy ecosystem. As protocols become more standardized and infrastructure expands, we anticipate a surge in late-stage trials and first approvals for non-melanoma indications, driving both clinical and commercial momentum.

Cumulative Impact of United States Tariffs on TIL Therapy Supply Chains in 2025

Beginning in early 2025, newly imposed tariffs on imported cell culture media, specialized reagents, and critical bioreactor components will reshape supply chain economics for TIL therapy developers. With duties ranging up to 15%, the cost of goods sold for ex vivo expansion processes is projected to rise, placing pressure on margins and potentially delaying clinical programs that rely on outsourced manufacturing.

Companies are already responding by diversifying their supplier base, qualifying domestic sources for key reagents, and investing in in-house manufacturing capabilities to mitigate tariff exposure. Strategic partnerships with contract manufacturing organizations that maintain local production sites have become a priority, as have negotiations for tariff exemptions under research-oriented trade provisions.

In parallel, raw material manufacturers are exploring tariff engineering solutions-such as reclassifying inputs under existing trade agreements-and pursuing joint ventures in the United States to preserve competitive pricing. Regulatory teams are coordinating with customs authorities to expedite approvals for critical components, while supply chain leaders are adopting advanced tracking systems to optimize inventory and reduce duty liabilities.

Together, these measures will help sustain the momentum of TIL therapy development and ensure that emerging therapies remain financially viable, even under a more restrictive trade policy environment.

Key Segmentation Insights Across Indication, Cell Source, End User, Distribution and Manufacturing Models

Insight into indication segmentation reveals that melanoma programs continue to dominate early pipelines, yet lung cancer and breast cancer trials are rapidly expanding as efficacy data matures. When considering cell source, autologous approaches remain the cornerstone of personalized therapy development, while allogeneic platforms are gaining traction for their potential to lower manufacturing costs and streamline dosing schedules. Analysis of end users indicates that academic hospitals and specialty clinics are spearheading clinical adoption, with research institutes driving preclinical innovation and informing novel combination strategies.

Distribution channel dynamics show that hospital pharmacy departments are the primary dispensing sites for TIL products, while online pharmacy models are emerging to facilitate decentralized administration and patient monitoring. Retail pharmacy participation remains limited but may grow as commercial approvals increase. Finally, manufacturing model segmentation highlights a clear divide: contract manufacturing organizations are preferred for early-stage and small-batch production due to their technical expertise, whereas leading biotechs are investing in in-house manufacturing to secure scale, reduce time to market, and protect intellectual property.

Regional Dynamics Shaping the Tumor-Infiltrating Lymphocyte Therapy Market

In the Americas, robust venture funding and a favorable regulatory environment have accelerated late-stage trials, particularly in melanoma and non-small cell lung cancer. Centers of excellence in the United States are pioneering combination studies with checkpoint inhibitors, fueling regional leadership and cross-border partnerships with Canadian and Latin American institutions. Europe, Middle East & Africa exhibit a growing emphasis on harmonized clinical protocols and joint procurement initiatives, underpinned by expanding GMP-compliant manufacturing hubs in Western Europe and Israel. Regulatory agencies across the region are increasingly aligned with FDA guidance, reducing approval timelines and fostering pan-regional trial networks.

In Asia-Pacific, government-backed immunotherapy initiatives in China, Japan, and Australia are driving large-scale trial enrollment and domestic production capabilities. National reimbursement frameworks are evolving to include high-cost cell therapies, supporting broader patient access. Collaborative efforts between academic research centers and local biopharma firms are accelerating knowledge transfer and laying the groundwork for future commercial launches. While infrastructure and regulatory maturity vary, the region’s sizable patient populations and growing clinical expertise make it a critical growth frontier for TIL therapy development.

Competitive Landscape: Leading Companies Driving TIL Therapy Advancements

The competitive landscape features a mix of specialized biotechs and global immuno-oncology leaders. Key players have diversified their pipelines beyond melanoma, advancing cell source innovations such as gene-edited allogeneic platforms. Strategic partnerships abound: leading cell therapy firms collaborate with large pharmaceutical companies to co-develop combination regimens, while alliances with equipment manufacturers enable access to next-generation bioreactor systems.

Several companies have also secured exclusive supply agreements with reagent providers to ensure priority access to critical reagents. Others are partnering with digital health startups to integrate real-time monitoring and predictive analytics into clinical workflows, improving patient safety and streamlining data collection. Manufacturing scale-up strategies include both greenfield facility investments and expansions of existing contract manufacturing networks, ensuring capacity aligns with anticipated commercial demand.

Innovation extends to business models as well; some organizations offer reagent-as-a-service subscriptions to academic labs, while others provide end-to-end manufacturing services for emerging developers. This diversity of approaches underscores a rapidly evolving ecosystem in which collaboration, agility, and technical excellence will determine market leadership.

Actionable Recommendations for Industry Leaders in TIL Therapy Development

To navigate this dynamic environment, industry leaders should prioritize automation and closed-system manufacturing to drive reproducibility and cost efficiency. Establishing strategic alliances with contract development and manufacturing organizations can accelerate scale-up while preserving capital for clinical expansion. Early engagement with regulatory authorities, leveraging breakthrough designations and accelerated approval pathways, will facilitate faster market entry and competitive positioning.

Leaders should also invest in digital platforms that enable remote patient monitoring and decentralized administration, thereby expanding trial reach and enhancing patient engagement. Building robust health economics and outcomes research capabilities will support reimbursement discussions and demonstrate real-world value. Companies should explore modular manufacturing models to adapt capacity based on pipeline milestones, minimizing financial risk.

Finally, fostering collaboration between R&D, manufacturing, and commercial teams is essential for aligning scientific innovation with market needs and reimbursement realities. This cross-functional integration will ensure that products are developed with both clinical efficacy and commercial viability in mind, positioning organizations for sustainable growth in the TIL therapy space.

Research Methodology for Analyzing the TIL Therapy Market

This analysis combines comprehensive secondary research with primary interviews to ensure depth and accuracy. We reviewed peer-reviewed journals, regulatory filings, patent databases, and conference proceedings to map scientific and commercial developments. Industry experts-including clinicians, manufacturing specialists, and regulatory consultants-provided insights into emerging trends, operational challenges, and strategic priorities.

Data triangulation methods validated findings across multiple sources, while qualitative analysis of company presentations and investor materials identified business model innovations and competitive dynamics. Regional assessments incorporated local regulatory guidelines, reimbursement policies, and clinical trial registries to capture geographic nuances. Segmentation frameworks were developed to standardize comparisons across indication, cell source, end user, distribution channel, and manufacturing model.

To ensure methodological rigor, all data points were cross-checked, and conflicting information was resolved through follow-up consultations with subject-matter experts. Our approach delivers a reliable, unbiased foundation for strategic decision-making, enabling stakeholders to act with confidence in this rapidly evolving market.

Conclusion

Tumor-infiltrating lymphocyte therapy stands at the forefront of personalized immuno-oncology, offering new hope for patients with solid tumors. As manufacturing processes become more streamlined and regulatory pathways evolve, the field is poised for significant expansion. However, challenges related to supply chain stability, reimbursement frameworks, and competitive differentiation remain.

By understanding key segmentation and regional dynamics, engaging with leading partners, and implementing strategic recommendations, stakeholders can navigate this complex landscape effectively. The insights presented here provide a foundation for informed investment, development, and commercialization strategies, ensuring that organizations capitalize on the full potential of TIL therapy innovation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Breast Cancer
    • Lung Cancer
    • Melanoma
  • Cell Source
    • Allogeneic
    • Autologous
  • End User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Manufacturing Model
    • Contract Manufacturing Organization
    • In-House Manufacturing
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Iovance Biotherapeutics, Inc.
  • Marker Therapeutics, Inc.
  • TILT Biotherapeutics
  • Instill Bio
  • Achilles Therapeutics

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tumor-Infiltrating Lymphocyte Therapy Market, by Therapeutic Applications
8.1. Introduction
8.2. Breast Cancer
8.3. Cervical Cancer
8.4. Colorectal Cancer
8.5. Lung Cancer
8.6. Melanoma
8.7. Renal Cell Carcinoma
9. Tumor-Infiltrating Lymphocyte Therapy Market, by Cell Source Origin
9.1. Introduction
9.2. Allogeneic Tumor-Infiltrating Lymphocytes
9.3. Autologous Tumor-Infiltrating Lymphocytes
9.4. Peripheral Blood Lymphocytes
10. Tumor-Infiltrating Lymphocyte Therapy Market, by Manufacturing Technology
10.1. Introduction
10.2. Cell Culture Techniques
10.2.1. 2D Culture Systems
10.2.2. 3D Culture Systems
10.2.2.1. Hydrogel Systems
10.2.2.2. Microcarrier Systems
10.3. Expansion Techniques
10.3.1. Rapid Expansion Protocols
10.3.2. Slow Expansion Protocols
10.4. Gene Modification Techniques
10.4.1. CAR-T
10.4.2. CRISPR
10.4.3. TALEN
11. Tumor-Infiltrating Lymphocyte Therapy Market, by Patient Demographics
11.1. Introduction
11.2. Adult
11.2.1. Elderly
11.2.2. Middle-Aged Adults
11.2.3. Young Adults
11.3. Pediatric
12. Tumor-Infiltrating Lymphocyte Therapy Market, by Type Of Therapy
12.1. Introduction
12.2. Combination Therapy
12.2.1. With Chemotherapy
12.2.2. With Radiation Therapy
12.3. Monotherapy
13. Tumor-Infiltrating Lymphocyte Therapy Market, by End-User
13.1. Introduction
13.2. Cancer Research Institutes
13.3. Hospitals
13.4. Specialty Clinics
14. Tumor-Infiltrating Lymphocyte Therapy Market, by Development Stage
14.1. Introduction
14.2. Clinical Trials
14.3. Preclinical
15. Tumor-Infiltrating Lymphocyte Therapy Market, by Mechanism Of Action
15.1. Introduction
15.2. Cytotoxicity
15.3. Immune Modulation
15.4. Lymphokine-Activated Killing
16. Tumor-Infiltrating Lymphocyte Therapy Market, by Safety And Efficacy Measures
16.1. Introduction
16.2. Adverse Effects
16.3. Therapeutic Index
17. Americas Tumor-Infiltrating Lymphocyte Therapy Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Tumor-Infiltrating Lymphocyte Therapy Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Achilles Therapeutics plc
20.3.2. Adaptimmune Therapeutics plc
20.3.3. Autolus Therapeutics plc
20.3.4. BrightPath Biotherapeutics Co., Ltd.
20.3.5. Celyad Oncology SA
20.3.6. Immatics N.V.
20.3.7. Instil Bio, Inc.
20.3.8. Iovance Biotherapeutics, Inc.
20.3.9. Kite Pharma, a Gilead Company
20.3.10. Lion TCR Pte. Ltd.
20.3.11. Lytix Biopharma AS
20.3.12. Marker Therapeutics, Inc.
20.3.13. Medigene AG
20.3.14. Precision Biosciences, Inc.
20.3.15. Tessa Therapeutics Pte. Ltd.
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET MULTI-CURRENCY
FIGURE 2. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 22. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2024 VS 2030 (%)
FIGURE 24. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC TUMOR-INFILTRATING LYMPHOCYTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PERIPHERAL BLOOD LYMPHOCYTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HYDROGEL SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MICROCARRIER SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RAPID EXPANSION PROTOCOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SLOW EXPANSION PROTOCOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CAR-T, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CRISPR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TALEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY WITH RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CYTOTOXICITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IMMUNE MODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LYMPHOKINE-ACTIVATED KILLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADVERSE EFFECTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC INDEX, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 107. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 108. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 109. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 111. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 112. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 113. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 114. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 115. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 116. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 118. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 120. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 121. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 122. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 124. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 126. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 128. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 129. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 131. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 132. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 133. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 135. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 184. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 185. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 186. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 188. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 189. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 190. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 191. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 192. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 193. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 194. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 195. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 197. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 198. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 199. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 200. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 201. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 203. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 204. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 205. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 206. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 207. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 208. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 209. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 210. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 212. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 213. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 229. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 230. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 231. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 233. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 234. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 235. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 236. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 237. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 238. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 239. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 240. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 242. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 243. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 244. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 247. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 248. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 249. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 264. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 267. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 268. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 270. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 272. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 276. SINGAPORE TUMOR-INFILTRATING LYMPHOCYTE TH

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tumor-Infiltrating Lymphocyte Therapy market report include:
  • Iovance Biotherapeutics, Inc.
  • Marker Therapeutics, Inc.
  • TILT Biotherapeutics
  • Instill Bio
  • Achilles Therapeutics

Related Topics

Related Reports

Tumor Infiltrating Lymphocytes Market Report 2025 - Product Image

Tumor Infiltrating Lymphocytes Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cellular Immunotherapy Market by Type, Technology Type, Indication, Institution Category - Global Forecast to 2030 - Product Image

Cellular Immunotherapy Market by Type, Technology Type, Indication, Institution Category - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
TIL Therapy - Pipeline Insight, 2025 - Product Image

TIL Therapy - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Cellular Immunotherapy Market Report 2025 - Product Image

Cellular Immunotherapy Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Molecular Targets and Cancer Therapeutics (Part 1) - Product Image

Molecular Targets and Cancer Therapeutics (Part 1)

  • Book
Copyright © 2002-2025 Research and Markets. All Rights Reserved.